Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Evaxion A/S as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q1 2026
- Shares held
- 1.59M
- +48.8K (+3.2%) vs. Q1 2026
- Total value
- $4.93M
- −$805.1K (−14.0%) vs. Q1 2026
- New holders
- 3
- 2 more added
- Sold out
- 1
- 5 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $4.93M |
| Q1 2026 | 17 | $5.74M |
| Q4 2025 | 15 | $6.81M |
| Q3 2025 | 8 | $5.00M |
| Q2 2025 | 9 | $3.27M |
| Q1 2025 | 10 | $2.50M |
| Q4 2024 | 10 | $681.8K |
| Q3 2024 | 8 | $1.71M |
| Q2 2024 | 6 | $1.31M |
| Q1 2024 | 6 | $1.22M |
| Q4 2023 | 9 | $314.2K |
| Q3 2023 | 10 | $115.9K |
| Q2 2023 | 9 | $209.8K |
| Q1 2023 | 9 | $291.4K |
| Q4 2022 | 8 | $166.9K |
| Q3 2022 | 6 | $377.0K |
| Q2 2022 | 9 | $442.0K |
| Q1 2022 | 12 | $2.06M |
| Q4 2021 | 12 | $4.76M |
| Q3 2021 | 7 | $3.28M |
| Q2 2021 | 7 | $3.33M |
| Q1 2021 | 10 | $5.12M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Evaxion A/S; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bessemer Group Inc | 18 | $0 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 62 | $192 | 0.00% | 00.0% | Unchanged |
| GAMMA Investing LLC | 4,612 | $14.3K | 0.00% | −586−11.3% | Reduced |
| UBS Group AG | 6,275 | $19.5K | 0.00% | +6,275 | New |
| Northwestern Mutual Wealth Management Co | 8,000 | $24.8K | 0.00% | 00.0% | Unchanged |
| Wesbanco Bank Inc | 10,000 | $31.0K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 12,899 | $40.0K | 0.00% | −9,154−41.5% | Reduced |
| SmartHarvest Portfolios, LLC | 13,460 | $41.7K | 0.01% | −348−2.5% | Reduced |
| Stonepine Capital Management, LLC | 17,562 | $54.4K | 0.04% | −2,151−10.9% | Reduced |
| Boothbay Fund Management, LLC | 18,426 | $57.1K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 20,581 | $63.8K | 0.00% | +20,581 | New |
| Rhumbline Advisers | 21,849 | $67.7K | 0.00% | +190+0.9% | Added |
| J. Safra Sarasin Holding AG | 22,896 | $71.0K | 0.00% | +22,896 | New |
| Annis Gardner Whiting Capital Advisors, LLC | 30,000 | $93.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 33,800 | $104.8K | 0.00% | −5,425−13.8% | Reduced |
| Citadel Advisors LLC | 36,584 | $113.4K | 0.00% | +18,811+105.8% | Added |
| Rathbone Brothers plc | 45,723 | $141.7K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 74,698 | $231.6K | 0.04% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,214,126 | $3.76M | 0.71% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −2,266−100.0% | Sold out |